Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis

Summary

The goal of this clinical study is to learn more about the combination of study drugs seladelpar and cilofexor. The study will assess, the safety, tolerability, and effectiveness of the combination drugs versus both seladelpar alone and placebo, in participants with primary biliary cholangitis (PBC). The primary objective of this study is to determine whether the combination of seladelpar + cilofexor leads to greater alkaline phosphatase (ALP) reduction than seladelpar alone and describe the safety and tolerability of seladelpar + cilofexor.

Timeline

Start

2026-10

Primary completion

2028-06

Completion

2034-06

Drugs

Indications